Compare ClearPoint Neuro Inc (CLPT) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Kraft Heinz Co — how do they compare? ClearPoint Neuro Inc trades at $14.71 (market cap $454.21M), while Kraft Heinz Co trades at $24.37 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 64.4× ClearPoint Neuro Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | KHC | |
|---|---|---|
Market Cap | $454.21M | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $28.06 |
52-Week Low | $8.66 | $21.21 |
Enterprise Value | $488.79M | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Kraft Heinz (KHC) trades at $24.93, down 1.54% on the day, with a bearish technical signal and mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces profitability challenges with a negative net income margin of -13.64% and ROE of -8.78%. Recent news highlights CEO Steve Cahillane's turnaround strategy with increased marketing investments, while analysts remain cautious with only 11.43% buy ratings.
The stock presents a value opportunity with attractive valuation ratios (P/E 13.04, P/B 0.81) and 6.4% dividend yield, but significant risks include ongoing earnings erosion, competitive pressures, and high debt levels. The consensus price target of $24.00 suggests limited upside from current levels, requiring careful monitoring of the company's execution on its growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
